| Name | Title | Contact Details |
|---|
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.
JeNu Biosciences was founded by a leading Washington bio scientist and a medical technology entrepreneur. While working on an ultrasound device for topical drug delivery, they became curious about using ultrasound to improve cosmetic skin care product delivery. High energy ultrasound has been proven effective at pushing drugs through the skin, but in the process cells are damaged and high heat causes intense pain. But since cosmetics only need to be absorbed into the top layer of skin rather than through the skin like drugs they thought a low energy ultrasound device might work. After many attempts they proved that low energy ultrasound wouldn`t help on its own. At the same moment, they had the idea that lead to the JeNu System. Rather than using ultrasound energy to vibrate cells in the skin to open up pathways, what if they vibrated microspheres on the skin to open the pathways. This idea lead to patent application 20120271222 and JeNu Biosciences. Launched in 2009, JeNu spent close to $10MM and 5 years on research, development and engineering. JeNu Biosciences is now proud to present the JeNu System. It`s the first pain free, at home, quick way to increase absorption of your favorite skin care products. In just one minute per target area per day the JeNu system is clinically proven to increase absorption by up to 12 times, and improve the efficacy of skin care products by up to 40% in just 7 days.
Varian Medical Systems` vision is a world without fear of cancer. To meet this challenge, we equip the world with new tools for fighting cancer. Since the 1950s we have been producing tools that harness the power of X-ray energy to benefit humankind. Our history is one of pioneering developments in the fields of radiotherapy, radiosurgery, X-ray tube technology, digital image detectors, cargo screening, and non-destructive testing. Today, we have a robust product portfolio and long-standing relationships with many of the world`s leading clinicians. As Varian continues to grow, our staff of over 6,500 people in 70 sales and support offices around the globe is developing innovative, cost-effective solutions that help make the world a healthier place. Varian reserves the right to remove any comment for any reason and ban any user from its page at is sole discretion. Varian does not endorse user comments on its page and cannot confirm their accuracy. User comments do not necessarily represent the ideas, thoughts, beliefs, opinions or views of Varian, or any of its affiliates.
One of every nine Americans is a member of an Anthem, Inc. affiliated health plan. For us, that`s a tremendous privilege and responsibility. Our focus every day is on improving the lives of the people we serve and the health of our communities. The foundation of our work can be summarized by: Delivering consistent service and becoming faster and simpler with every action we take. Creating the best health care value for our customers Investing where returns are the greatest to make the best use of our current assets. Being a market leader in each of our chosen businesses. Continuing to advocate for responsible health care reform.
Alzheimer's Association is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.